Showing 1 - 2 results of 2 for search 'Mengxi Shen', query time: 0.02s Refine Results
  1. 1
    One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

    One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial by Fenghua Wang, Yuanzhi Yuan, Ling Wang, Xiaofeng Ye, Jingke Zhao, Mengxi Shen, Qi Zhang, Ding Xu, Guoyou Qin, Wei Zhang, Fei Yuan, Qing Chang, Peiquan Zhao, Fang Wang, Xiaodong Sun

    Published 2019-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Comparison between Spectral-domain and Swept-source OCT Angiography Scans for the Measurement of Hyperreflective Foci in Age-related Macular Degeneration

    Comparison between Spectral-domain and Swept-source OCT Angiography Scans for the Measurement of Hyperreflective Foci in Age-related Macular Degeneration by Gissel Herrera, MD, Yuxuan Cheng, PhD, Yamini Attiku, MD, Farhan E. Hiya, MD, Mengxi Shen, MD, PhD, Jeremy Liu, MD, Jie Lu, PhD, Alessandro Berni, MD, Omer Trivizki, MD, Jianqing Li, MD, Robert C. O’Brien, PhD, Giovanni Gregori, PhD, Ruikang K. Wang, PhD, Philip J. Rosenfeld, MD, PhD

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: